Choose Language
Select a language for news translation.
With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE: LLY ) ranks among the most profitable blue chip stocks to …
Written by Adria Cimino for The Motley Fool -> Viking is developing candidates in the high-growth weight loss drug market. The company’s lead candidate is in…
Jordi Visser argues Eli Lilly's AI infrastructure, proprietary metabolic data, and GLP-1 drugs could make it the world's largest company within 5 years. Lilly…
Written by Joe Tenebruso for The Motley Fool -> Investors are excited about retatrutide's potential. Rival drugmakers are finding it difficult to keep pace w…
At the Tribeca Festival, the director reunited with the cast of her film 30 years on and got candid about what the sapphic neo-noir meant to her then and now.
Aclaris Therapeutics Inc. (NASDAQ: ACRS ) is one of the top penny stocks to buy in investors’ stock portfolio . On May 8, Stifel reiterated a Hold rating on Ac…
Written by Reuben Gregg Brewer for The Motley Fool -> Eli Lilly is probably best known for its dominant GLP-1 drugs right now. The company's recent $3.8 bill…
Two drugs make up nearly two-thirds of Eli Lilly 's (NYSE: LLY) top line, generating around $12.8 billion in revenues in the first quarter of 2026. The two dru…
EXCLUSIVE: Executive producers Margaret Cho and Lilly Wachowski have wrapped production on transgender comedian Nina Nguyen’s debut stand-up special. Directed …
Written by Jeff Siegel for The Motley Fool -> Eli Lilly now controls roughly 60% of the GLP-1 market. International growth could become Lilly's next major ca…
Written by Reuben Gregg Brewer for The Motley Fool -> Wall Street likes stories, and a big one today is the huge demand for GLP-1 weight-loss drugs. Novo Nor…
